TABLE II.
First-Line Treatment by Sex and Age Group
| First-Line Treatment | Male (n = 1277) n (%) | Female (n = 1375) n (%) | Overall P Valuea | Individual P Valueb |
|---|---|---|---|---|
| Watchful waiting | 253 (20) | 302 (22) | 0.003 | 0.174 |
| R-mono | 144 (11) | 212 (15) | 0.002 | |
| R-chemo | 648 (51) | 636 (46) | 0.021 | |
| R-CHOP | 341 (27) | 300 (22) | ||
| R-CVP | 136 (11) | 164 (12) | ||
| R-Fludarabine | 107 (8) | 114 (8) | ||
| R-other | 64 (5) | 58 (4) | ||
| Other treatments | 232 (18) | 225 (16) | 0.219 | |
| Chemotherapy | 39 (3) | 32 (2) | ||
| Investigational therapy | 81 (6) | 77 (6) | ||
| XRT | 62 (5) | 63 (5) | ||
| Other non-investigational therapy | 2 (<1) | 13 (1) | ||
| Combined modality: XRT | 43 (3) | 36 (3) | ||
| Combined modality: BMT | 2 (<1) | 2 (<1) | ||
| Radioimmunotherapy | 3 (<1) | 2 (<1) | ||
| Rituximab dose intensity among patients receiving R-mono, R-chemoc | 0.496 | |||
| <0.9 | 221 (32) | 229 (31) | ||
| ≥0.9–1.1 | 371 (54) | 417 (57) | ||
| >1.1 | 90 (13) | 84 (12) | ||
| Maintenance treatment among patients receiving R-mono, R-chemo | 0.988 | |||
| R-maintenance | 257 (46) | 282 (46) | ||
| Observation | 304 (54) | 333 (54) | ||
| ≤60 years | n = 619 | n = 636 | ||
| Watchful waiting | 111 (18) | 128 (20) | 0.042 | 0.322 |
| R-mono | 48 (8) | 74 (12) | 0.020 | |
| R-chemo | 328 (53) | 322 (51) | 0.403 | |
| Other treatments | 132 (21) | 112 (18) | 0.096 | |
| 61–80 years | n = 571 | n = 617 | ||
| Watchful waiting | 121 (21) | 144 (23) | 0.485 | |
| R-mono | 78 (14) | 96 (16) | ||
| R-chemo | 285 (50) | 282 (46) | ||
| Other treatments | 87 (15) | 95 (15) | ||
| >80 years | n = 87 | n = 122 | ||
| Watchful waiting | 21 (24) | 30 (25) | 0.092 | |
| R-mono | 18 (21) | 42 (34) | ||
| R-chemo | 35 (40) | 32 (26) | ||
| Other treatments | 13 (15) | 18 (15) |
R-mono, rituximab monotherapy; R-chemo, rituximab plus chemotherapy; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone; R-CVP, rituximab plus cyclophosphamide, vincristine and prednisolone; R-Fludarabine, rituximab plus fludarabine with/without other chemotherapy; R-other, rituximab plus other chemotherapy; XRT, radiotherapy; BMT, bone marrow transplantation.
Pearson chi-square test.
P values obtained using a 2×2 contingency table for each possible treatment group using Pearson chi-square test.
Rituximab dose intensity less than 1 indicates that the received dose was less intense than expected (1 dose per 7-day cycle for R-mono and 21-day cycle for R-chemo). Missing data were excluded.